Ozempic (semaglutide 1 mg) UK research guide 2026

What is Ozempic?

Ozempic is Novo Nordisk's proprietary brand of semaglutide at doses of up to 1 mg per week, licensed in the UK for the treatment of type 2 diabetes mellitus in adults. First granted MHRA marketing authorisation in 2018, Ozempic delivers semaglutide via a weekly subcutaneous injection and is distinct from the same manufacturer's weight-management product Wegovy, which contains a higher 2.4 mg maintenance dose approved for a different indication. Ozempic became the highest-profile product in the incretin class globally between 2021 and 2024, driven in large part by widespread off-label prescribing for obesity — a use that is outside its MHRA licence and that contributed to significant supply disruption for patients who depend on it for diabetes management.

UK regulatory status

Ozempic is MHRA-licensed solely for type 2 diabetes in adults. It is not licensed for weight management; Novo Nordisk's separate weight-management product — Wegovy — carries that indication. NHS prescribing of Ozempic follows NICE guideline NG28 and is indicated as an add-on to metformin (or other first-line agents) when glycaemic targets are not met, particularly in patients where a GLP-1 receptor agonist is preferred for cardiovascular or weight-related reasons. The 2022–2024 supply crisis, driven by rapid global demand growth outpacing Novo Nordisk manufacturing capacity and compounded by off-label weight-loss prescribing, prompted the MHRA and NHS England to issue prescriber guidance prioritising supply for diabetes patients. By 2025, supply had largely stabilised and shortages were no longer a clinical concern in mainstream UK pharmacy.

Clinical evidence summary

The SUSTAIN programme (SUSTAIN-1 through 7) established semaglutide's glycaemic efficacy across a range of contexts. SUSTAIN-1 (monotherapy) demonstrated HbA1c reductions of 1.45–1.55% with 0.5 and 1.0 mg semaglutide at 30 weeks versus 0.02% for placebo. SUSTAIN-2 compared semaglutide with sitagliptin (a DPP-4 inhibitor), demonstrating superior HbA1c and weight outcomes. SUSTAIN-3 compared semaglutide 1.0 mg with exenatide 2 mg extended-release, with semaglutide achieving superior outcomes. SUSTAIN-6 was a cardiovascular outcomes trial in high-risk patients: semaglutide 0.5 and 1.0 mg reduced the composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 26% versus placebo over 2.1 years. SUSTAIN-7 compared semaglutide directly with dulaglutide and demonstrated significant advantages on both HbA1c and body weight. SUSTAIN-10 confirmed superiority over liraglutide 1.2 mg. The SELECT trial, conducted at the Wegovy dose (2.4 mg) in people with overweight or obesity and established cardiovascular disease without diabetes, demonstrated a 20% reduction in MACE — a landmark cardiovascular outcome for the GLP-1 class.

Mechanism

Semaglutide in Ozempic acts as a selective GLP-1 receptor agonist, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite via central hypothalamic pathways. It shares the same mechanism with Wegovy; the difference in clinical effects between doses reflects the dose–response relationship of the GLP-1 receptor. For the full mechanistic profile, see the semaglutide molecule page.

Dosing and administration

Ozempic is initiated at 0.25 mg weekly for the first four weeks (a tolerability-building dose, not a therapeutically effective dose). The dose is then increased to 0.5 mg weekly from week five, and may be escalated to 1.0 mg from week nine onwards if additional glycaemic control is required. A 2.0 mg dose is approved in some markets for patients not achieving adequate control on 1.0 mg, though the 1 mg dose is the standard upper limit in current UK MHRA labelling. The pen is administered subcutaneously into the abdomen, thigh, or upper arm; injection sites should be rotated.

Common side effects

Ozempic shares the GLP-1 class gastrointestinal side-effect profile. In the SUSTAIN programme, nausea was reported in approximately 20% of participants on active treatment, diarrhoea in approximately 12%, vomiting in approximately 5–9%, and constipation in approximately 3–5%. Adverse events are dose-dependent and predominantly occur during dose escalation. Discontinuation due to gastrointestinal adverse events occurred in approximately 3.9% of semaglutide-treated patients in SUSTAIN-6. Gallbladder events, including cholelithiasis, have been reported at higher rates than placebo, consistent with the broader GLP-1 class.

Ozempic vs Wegovy

The most clinically important comparison for UK researchers is between Ozempic and Wegovy — two products containing the same molecule from the same manufacturer, but licensed for different indications and at different doses.

See also: Wegovy brand guide · Rybelsus brand guide · Mounjaro brand guide.

Procurement and supplier position

This page is educational and does not advertise, sell, supply, recommend or rank any supplier, compounder, online pharmacy or telehealth service for Ozempic or any version of semaglutide. Ozempic is a UK prescription-only medicine licensed for type 2 diabetes and should only be accessed through a qualified UK prescriber following appropriate clinical assessment. Off-label, compounded or grey-market "semaglutide" is not the same regulated product as Ozempic. See UK POM context for GLP-1 medicines.

Frequently asked questions

Is Ozempic licensed for weight loss in the UK?

No. Ozempic (semaglutide 1 mg) is MHRA-licensed in the UK for the treatment of type 2 diabetes mellitus only. It is not licensed for weight management. Novo Nordisk's separate product Wegovy (semaglutide 2.4 mg) holds the weight-management licence. Prescribing Ozempic off-label for obesity is not endorsed and contributed to supply shortages between 2022 and 2024.

Is Ozempic the same as Wegovy?

Both contain semaglutide from Novo Nordisk, but at different doses and with different licensed indications. Ozempic delivers up to 1 mg (or 2 mg in some markets) weekly and is for type 2 diabetes. Wegovy delivers up to 2.4 mg weekly and is for weight management. The higher dose in Wegovy produces greater receptor occupancy and more pronounced central satiety effects, which is reflected in greater mean weight loss in the STEP trials compared to the SUSTAIN diabetes trials.

Was Ozempic affected by supply shortages?

Yes. Ozempic was significantly affected by global supply disruption between 2022 and 2024. Demand was driven partly by off-label prescribing for weight loss — fuelled by social-media attention — which compounded the capacity pressures Novo Nordisk faced in manufacturing semaglutide. The MHRA and NHS England issued guidance asking prescribers to prioritise Ozempic for patients with type 2 diabetes who depended on it. Supply had largely normalised by 2025.

What is the SELECT trial and does it apply to Ozempic?

The SELECT trial (2023) was a large cardiovascular outcomes trial in which semaglutide 2.4 mg (the Wegovy dose, not Ozempic) reduced major adverse cardiovascular events by 20% in people with established cardiovascular disease and overweight/obesity without diabetes. While SELECT used the higher dose, the class-level cardiovascular data from Ozempic's SUSTAIN-6 trial (3.8% reduction in MACE at 2 years) also provides important context for the cardiovascular benefits of semaglutide.

Can Ozempic be prescribed on the NHS for diabetes?

Yes. Ozempic is available on NHS prescription for the management of type 2 diabetes in adults. It is prescribed when diet and exercise adjustments plus first-line therapy such as metformin have been insufficient. NICE guidelines (NG28 update) recommend GLP-1 receptor agonists including semaglutide at specific points in the treatment algorithm.

What does Ozempic contain?

Each Ozempic FlexPen or FlexTouch pen contains semaglutide — a GLP-1 receptor agonist with two amino-acid substitutions relative to native GLP-1 to resist DPP-4 cleavage, and a C18 fatty-diacid moiety enabling albumin binding and a half-life of approximately seven days. The standard maintenance doses are 0.5 mg and 1.0 mg weekly; a 2.0 mg dose is approved in some markets.